PuraPharm 미래 성장

Future 기준 확인 0/6

현재 PuraPharm 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	11.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 PuraPharm 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:1498 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	419	-87	79	98	N/A
3/31/2024	413	-97	69	89	N/A
12/31/2023	407	-106	58	80	N/A
9/30/2023	410	-112	41	59	N/A
6/30/2023	412	-118	24	38	N/A
3/31/2023	430	-119	45	63	N/A
12/31/2022	448	-120	66	89	N/A
9/30/2022	518	-147	58	62	N/A
6/30/2022	588	-174	50	36	N/A
3/31/2022	624	-148	15	11	N/A
12/31/2021	660	-122	-21	-15	N/A
9/30/2021	642	-45	-17	33	N/A
6/30/2021	624	32	-12	81	N/A
3/31/2021	613	32	12	100	N/A
12/31/2020	602	32	37	120	N/A
9/30/2020	622	-69	48	129	N/A
6/30/2020	643	-171	59	138	N/A
3/31/2020	669	-199	61	135	N/A
12/31/2019	696	-227	63	131	N/A
9/30/2019	694	-132	60	108	N/A
6/30/2019	692	-38	58	84	N/A
3/31/2019	719	-8	41	78	N/A
12/31/2018	746	21	25	72	N/A
9/30/2018	730	13	0	78	N/A
6/30/2018	715	6	-24	83	N/A
3/31/2018	653	4	N/A	20	N/A
12/31/2017	592	2	N/A	-43	N/A
9/30/2017	589	17	N/A	-70	N/A
6/30/2017	587	33	N/A	-97	N/A
3/31/2017	561	33	N/A	-76	N/A
12/31/2016	536	32	N/A	-56	N/A
9/30/2016	518	38	N/A	-49	N/A
6/30/2016	499	44	N/A	-42	N/A
3/31/2016	487	36	N/A	-27	N/A
12/31/2015	474	28	N/A	-13	N/A
9/30/2015	436	24	N/A	4	N/A
6/30/2015	398	20	N/A	21	N/A
3/31/2015	382	27	N/A	26	N/A
12/31/2014	366	34	N/A	31	N/A
12/31/2013	342	26	N/A	11	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 1498 의 예상 수익 증가율이 절약률( 2.3% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 1498 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1498 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 1498 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 1498 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 1498 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

PuraPharm 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견